Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9161559rdf:typepubmed:Citationlld:pubmed
pubmed-article:9161559lifeskim:mentionsumls-concept:C0017086lld:lifeskim
pubmed-article:9161559lifeskim:mentionsumls-concept:C1883674lld:lifeskim
pubmed-article:9161559lifeskim:mentionsumls-concept:C0034734lld:lifeskim
pubmed-article:9161559lifeskim:mentionsumls-concept:C0002199lld:lifeskim
pubmed-article:9161559lifeskim:mentionsumls-concept:C2709058lld:lifeskim
pubmed-article:9161559lifeskim:mentionsumls-concept:C0231242lld:lifeskim
pubmed-article:9161559pubmed:issue4lld:pubmed
pubmed-article:9161559pubmed:dateCreated1997-6-4lld:pubmed
pubmed-article:9161559pubmed:abstractTextIn a 43-year old male suffering from idiopathic hypereosinophilic syndrome (HES) since 1984, successfully treated with alpha interferon (alpha IFN) for 32 months, a severe Raynaud's phenomenon of the four extremities occurred and eventually evolved into digital necrosis within a few weeks. The arterial echography/doppler and plethysmography patterns were suggestive of isolated small-to medium-size digital artery occlusions. An extensive search for an aetiology of digital necrosis, including complete tests of autoimmunity, remained negative. Two months later, despite alpha IFN withdrawal and intravenous infusions of ilomedin, the digital ischemia evolved to extensive necrosis that necessitated several amputations and a definitive spinal chord stimulation. Pathologic examination of arteries showed no vasculitis but diffuse arterial occlusions by thrombi.lld:pubmed
pubmed-article:9161559pubmed:languagefrelld:pubmed
pubmed-article:9161559pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9161559pubmed:citationSubsetIMlld:pubmed
pubmed-article:9161559pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9161559pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9161559pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9161559pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9161559pubmed:statusMEDLINElld:pubmed
pubmed-article:9161559pubmed:issn0248-8663lld:pubmed
pubmed-article:9161559pubmed:authorpubmed-author:VidalEElld:pubmed
pubmed-article:9161559pubmed:authorpubmed-author:LabrousseFFlld:pubmed
pubmed-article:9161559pubmed:authorpubmed-author:LiozonFFlld:pubmed
pubmed-article:9161559pubmed:authorpubmed-author:VidalJJlld:pubmed
pubmed-article:9161559pubmed:authorpubmed-author:LacroixPPlld:pubmed
pubmed-article:9161559pubmed:authorpubmed-author:MaRRlld:pubmed
pubmed-article:9161559pubmed:authorpubmed-author:LiozonEElld:pubmed
pubmed-article:9161559pubmed:authorpubmed-author:DelaireLLlld:pubmed
pubmed-article:9161559pubmed:authorpubmed-author:Loustaud-Ratt...lld:pubmed
pubmed-article:9161559pubmed:authorpubmed-author:FauchaisA LALlld:pubmed
pubmed-article:9161559pubmed:issnTypePrintlld:pubmed
pubmed-article:9161559pubmed:volume18lld:pubmed
pubmed-article:9161559pubmed:ownerNLMlld:pubmed
pubmed-article:9161559pubmed:authorsCompleteYlld:pubmed
pubmed-article:9161559pubmed:pagination316-9lld:pubmed
pubmed-article:9161559pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:9161559pubmed:meshHeadingpubmed-meshheading:9161559-...lld:pubmed
pubmed-article:9161559pubmed:meshHeadingpubmed-meshheading:9161559-...lld:pubmed
pubmed-article:9161559pubmed:meshHeadingpubmed-meshheading:9161559-...lld:pubmed
pubmed-article:9161559pubmed:meshHeadingpubmed-meshheading:9161559-...lld:pubmed
pubmed-article:9161559pubmed:meshHeadingpubmed-meshheading:9161559-...lld:pubmed
pubmed-article:9161559pubmed:meshHeadingpubmed-meshheading:9161559-...lld:pubmed
pubmed-article:9161559pubmed:meshHeadingpubmed-meshheading:9161559-...lld:pubmed
pubmed-article:9161559pubmed:meshHeadingpubmed-meshheading:9161559-...lld:pubmed
pubmed-article:9161559pubmed:meshHeadingpubmed-meshheading:9161559-...lld:pubmed
pubmed-article:9161559pubmed:meshHeadingpubmed-meshheading:9161559-...lld:pubmed
pubmed-article:9161559pubmed:meshHeadingpubmed-meshheading:9161559-...lld:pubmed
pubmed-article:9161559pubmed:meshHeadingpubmed-meshheading:9161559-...lld:pubmed
pubmed-article:9161559pubmed:year1997lld:pubmed
pubmed-article:9161559pubmed:articleTitle[Raynaud syndrome complicated by digital gangrene during treatment with interferon-alpha].lld:pubmed
pubmed-article:9161559pubmed:affiliationService de médecine interne A, CHU Dupuytren, Limoges, France.lld:pubmed
pubmed-article:9161559pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9161559pubmed:publicationTypeEnglish Abstractlld:pubmed
pubmed-article:9161559pubmed:publicationTypeCase Reportslld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9161559lld:pubmed